Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Slightly Bullish +25

Cigna abandons pursuit of Humana, plans $10 billion share buyback

🚫 Cigna has officially abandoned its negotiations to acquire rival Humana due to an inability to agree on price.

💼 The failed deal would have created a combined entity valued at over $140 billion, positioning them against UnitedHealth Group and CVS Health.

⚠️ Regulatory antitrust concerns are a major factor, as similar mega-deals like Anthem-Elevance and Aetna-CVS previously failed or faced court blocks.

💰 Cigna announced an additional $10 billion share buyback program, bringing total repurchases to $11.3 billion for the current period.

📉 Cigna's CEO David Cordani stated shares are undervalued and repurchases will support high-quality care and affordability initiatives.

🏥 Cigna is also exploring the sale of its Medicare Advantage business, which has disappointed investors and operates in an area where Humana is dominant.

🔄 Selling its Medicare Advantage operations could potentially boost future merger prospects by alleviating some antitrust hurdles, according to legal experts.

🗣️ Both Humana and Cigna declined to provide further comments on the ongoing deal talks or the share buyback plans.

📅 These discussions occurred six years after regulators previously blocked attempts to consolidate the U.S. health insurance sector.

🏛️ The failed merger highlights the significant scale and market overlap between the two companies, particularly in plans for Americans aged 65 and older.

Bullish Signals
  • Cigna announced plans to repurchase $10 billion worth of its own shares, with total repurchases now reaching $11.3 billion.
  • CEO David Cordani stated the company's shares are significantly undervalued, positioning this capital deployment as value-enhancing for shareholders.
  • Management signaled openness to future bolt-on acquisitions and value-enhancing divestitures that align with corporate strategy.
Risk Factors
  • Cigna's attempt to acquire rival Humana has failed due to an inability to agree on a price, ending potential synergies that could have allowed the combined entity to rival larger competitors like UnitedHealth Group and CVS Health.
  • The failed merger talks highlight significant regulatory headwinds, as a combination of Cigna ($77 billion) and Humana ($59 billion) would have attracted fierce antitrust scrutiny following previous blocked mega-deals in the sector.
  • Cigna is exploring the sale of its Medicare Advantage business, a strategic reversal that acknowledges disappointing investor performance in this specific segment.
  • Historical precedent poses a persistent regulatory risk, as Anthem (now Elevance Health) lost a $48 billion bid for Cigna and Aetna abandoned a $37 billion bid for Humana after U.S. courts upheld antitrust challenges.
  • The company's decision to pursue share buybacks ($10 billion additional, totaling $11.3 billion) as a value-enhancing measure may signal an inability to generate sufficient organic growth or profitability to justify expansion through acquisition.
Full Analysis
Cigna has officially ended negotiations to acquire rival Humana after the two companies failed to reach an agreement on price. A combination of the two insurers would have formed a entity valued at over $140 billion, creating significant scale to compete with larger players like UnitedHealth Group and CVS Health, but it would have likely faced severe antitrust scrutiny similar to past blocked deals in the sector. Sources indicate that the talks collapsed specifically due to disagreements on valuation, though a potential tie-up remains a possibility for the future if conditions change. To replace capital intended for the failed acquisition, Cigna announced plans to execute a $10 billion share buyback program, bringing its total repurchase authorization to $11.3 billion. CEO David Cordani stated in a statement that the company believes its shares are significantly undervalued and that using capital for repurchases will enhance value while supporting high-quality care and affordability. This shift also comes as Cigna explores selling its Medicare Advantage business, which has previously disappointed investors, marking a strategic reversal from its prior expansion in that sector. The failed merger talks highlight the intense antitrust pressures facing the U.S. health insurance market, where regulators have historically blocked consolidation. Previous attempts by Aetna and Anthem to merge with Humana or Cigna respectively were rejected or abandoned due to legal challenges. Economists note that divesting Cigna's Medicare Advantage operations could have improved its chances of surviving regulatory review in a future deal, but the current impasse has led to a pivot toward share buybacks and potential asset sales instead.